Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1Endocrine 1

Conditions

Purpura, Thrombocytopenic, Idiopathic 3Lymphoma 3Pheochromocytoma 1Ovarian Neoplasms 1Neoplasms 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Liver Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Sorafenib 23Bevacizumab 11Radiosurgery 6Capecitabine 6Radiofrequency Ablation 5Oxaliplatin 5Fluorouracil 5Doxorubicin 5pembrolizumab 4Sunitinib 4Erlotinib Hydrochloride 4Cisplatin 4Ramucirumab 3Radiotherapy 3Nivolumab 3Leucovorin 3Carboplatin 3tremelimumab 2spartalizumab 2perflutren 2derazantinib 2carotuximab 2Mitomycin 2Magnetic Resonance Spectroscopy 2Magnetic Resonance Imaging 2Ipilimumab 2Immunohistochemistry 2Gemcitabine 2Folfox protocol 2Fluorodeoxyglucose F18 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Liver Neoplasms × fostamatinib × Clear all
NCT00923481 2015-09-30

A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
37 enrolled 10 charts
EndocrineGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Kidney Neoplasms, Liver Neoplasms, Neoplasms, Pheochromocytoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡